|
1
|
Nagini S: Carcinoma of the stomach: A
review of epidemiology, pathogenesis, molecular genetics and
chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertuccio P, Chatenoud L, Levi F, Praud D,
Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent patterns in
gastric cancer: A global overview. Int J Cancer. 125:666–673. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bergis D, Kassis V and Radeke HH: High
plasma sST2 levels in gastric cancer and their association with
metastatic disease. Cancer Biomark. 16:117–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN,
Shao JP and Ji H: IL-33-induced JNK pathway activation confers
gastric cancer chemotherapy resistance. Oncol Rep. 33:2746–2752.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ and
Hu WH: IL-33 promotes gastric cancer cell invasion and migration
via ST2-ERK1/2 pathway. Dig Dis Sci. 60:1265–1272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikeguchi M, Hatada T, Yamamoto M, Miyake
T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H and Tatebe
S: Serum interleukin-6 and −10 levels in patients with gastric
cancer. Gastric Cancer. 12:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang JS, Bae SY, Kim HR, Kim YS, Kim DJ,
Cho BJ, Yang HK, Hwang YI, Kim KJ, Park HS, et al: Interleukin-18
increases metastasis and immune escape of stomach cancer via the
downregulation of CD70 and maintenance of CD44. Carcinogenesis.
30:1987–1996. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haghshenas MR, Hosseini SV, Mahmoudi M,
Saberi-Firozi M, Farjadian S and Ghaderi A: IL-18 serum level and
IL-18 promoter gene polymorphism in Iranian patients with
gastrointestinal cancers. J Gastroenterol Hepatol. 24:1119–1122.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmitz J, Owyang A, Oldham E, Song Y,
Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et
al: IL-33, an interleukin-1-like cytokine that signals via the IL-1
receptor-related protein ST2 and induces T helper type 2-associated
cytokines. Immunity. 23:479–490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mirchandani AS, Salmond RJ and Liew FY:
Interleukin-33 and the function of innate lymphoid cells. Trends
Immunol. 33:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Shen JX, Hu JL, Huang WH and Zhang
GJ: Significance of interleukin-33 and its related cytokines in
patients with breast cancers. Front Immunol. 5:1412014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mohran ZY, Ali-Eldin FA and Abdel Aal HA:
Serum interleukin-18: Does it have a role in the diagnosis of
hepatitis C virus related hepatocellular carcinoma? Arab J
Gastroenterol. 12:29–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Musolino C, Allegra A, Profita M, Alonci
A, Saitta S, Russo S, Bonanno A, Innao V and Gangemi S: Reduced
IL-33 plasma levels in multiple myeloma patients are associated
with more advanced stage of disease. Br J Haematol. 160:709–710.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun P, Ben Q, Tu S, Dong W, Qi X and Wu Y:
Serum interleukin-33 levels in patients with gastric cancer. Dig
Dis Sci. 56:3596–3601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu W and Wu C, Li X, Zheng Z, Xie Q, Deng
X, Jiang J and Wu C: Serum IL-33 level is a predictor of
progression-free survival after chemotherapy. Oncotarget.
8:35116–35123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu W, Li X, Li Q, Tan Y, Xu B, Xie Q, Deng
X, Lu B, Jiang J and Wu C: Interleukin-33 expression does not
correlate with survival of gastric cancer patients. Pathol Oncol
Res. 23:615–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak JK and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Santulli P, Even M, Chouzenoux S,
Millischer AE, Borghese B, de Ziegler D, Batteux F and Chapron C:
Profibrotic interleukin-33 is correlated with uterine leiomyoma
tumour burden. Hum Reprod. 28:2126–2133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang P, Liu XK, Chu Z, Ye JC, Li KL,
Zhuang WL, Yang DJ and Jiang YF: Detection of interleukin-33 in
serum and carcinoma tissue from patients with hepatocellular
carcinoma and its clinical implications. J Int Med Res.
40:1654–1661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai F, Ba F, You Y, Feng Y, Tao W, Wu C,
Jiu M and Nie Y: Decreased ST2 expression is associated with
gastric cancer progression and pathogenesis. Oncol Lett.
17:5761–5767. 2019.PubMed/NCBI
|
|
21
|
Trajkovic V, Sweet MJ and Xu D: T1/ST2-an
IL-1 receptor-like modulator of immune responses. Cytokine Growth
Factor Rev. 15:87–95. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Wu K, Cai K, Zhai R, Tao K, Wang G
and Wang J: Increased numbers of gastric-infiltrating mast cells
and regulatory T cells are associated with tumor stage in gastric
adenocarcinoma patients. Oncol Lett. 4:755–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eissmann MF, Dijkstra C, Jarnicki A,
Phesse T, Brunnberg J, Poh AR, Etemadi N, Tsantikos E, Thiem S,
Huntington ND, et al: IL-33-mediated mast cell activation promotes
gastric cancer through macrophage mobilization. Nat Commun.
10:27352019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chackerian AA, Oldham ER, Murphy EE,
Schmitz J, Pflanz S and Kastelein RA: IL-1 receptor accessory
protein and ST2 comprise the IL-33 receptor complex. J Immunol.
179:2551–2555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Wang F, Fan L, Zhang W, Wang T, Du Y
and Bai X: Baicalin alleviates atherosclerosis by relieving
oxidative stress and inflammatory responses via inactivating the
NF-κB and p38 MAPK signaling pathways. Biomed Pharmacother.
97:1673–1679. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jovanovic IP, Pejnovic NN, Radosavljevic
GD, Arsenijevic NN and Lukic ML: IL-33/ST2 axis in innate and
acquired immunity to tumors. Oncoimmunology. 1:229–231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sui X, Kong N, Ye L, Han W, Zhou J, Zhang
Q, He C and Pan H: p38 and JNK MAPK pathways control the balance of
apoptosis and autophagy in response to chemotherapeutic agents.
Cancer Lett. 344:174–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
